PET scans or “Positron emission tomography” is a functional imaging modality, initially introduced for neurological research in the early 1970s. However, currently, this imaging modality forms the back-bone of oncological imaging and is one of the most requested investigations for evaluation of solid cancers. The commercial availability of radiopharmaceutical F-18 FDG (Fluoro-deoxy glucose) or radio-labelled glucose and fusion imaging modality such as PET CT, has helped its advancement from research laboratory to active clinical practice in the early 2000s.
F-18 FDG PET CT scans are usually whole-body examinations which provide information about the structure and function of the tumour or cancer tissue. Apart from cancer imaging, F-18 FDG PET scans of the brain are quite popular and are used for evaluation of neurological disorders like dementia, epilepsy, movement disorders, encephalitis and other psychiatric diseases. Another important application is Cardiac PET scan which aims at diagnosis of myocardial viability or living tissue within the heart. This helps the cardiologists to decide the best treatment for patients with coronary artery disease (CAD).
Globally, a lot of research is going on for the development of newer imaging molecules and radiotracers for PET CT scans. A decade back, Gallium-68 (Ga-68) labelled tracers were introduced for PET CT imaging e.g Ga-68 labelled DOTANOC and PSMA for evaluation of neuroendocrine tumours and prostate cancers. These molecules readily found acceptance among oncologists for evaluation of these malignancies.
These are among the newest radiopharmaceuticals available for PET CT scans in our department. With the availability of these radiopharmaceuticals, we offer the entire spectrum of PET CT scans in our department.
(I) F-18 PSMA PET CT scan: F-18 PSMA is a radiopharmaceutical designed for PET CT imaging of prostate cancers. Prostate cancer is one of the most common cancers of elderly males. F-18 PSMA PET CT scan is currently used for following indications in prostate cancers:
Diagnosis and staging of the disease
Early treatment response evaluation, to differentiate between responder & non-responder
Detection of early recurrence
Evaluation of metastatic sites in prostate malignancy
(II) F-18 Fluorodopa PET CT scan: Primarily, this radiopharmaceutical is used for diagnosis and evaluation of Parkinson’s disease and other movement disorders. However, these scans are also helpful in the evaluation of primary brain tumours (Gliomas), Medullary carcinoma of the thyroid and neuroendocrine cancers.
Indications of F-18 Fluorodopa PET CT scans are:
Diagnosis of Parkinson’s disease and other movement disorders
Diagnosis of primary brain tumours e.g. Gliomas
Radiotherapy planning of primary brain tumours
Diagnosis, treatment response evaluation and detection of recurrence in medullary carcinoma thyroid
Evaluation of Neuro-endocrine tumours like Neuroblastomas, Phaeochromocytomas etc
Consultant and Head
An antibody test is a blood test used to detect antibodies formed in the body against a pathogen as a defensive response by the immune system towards…
Till a few months back, you might have heard the job title “Anaesthetist” and most of you would have said “ they put people to sleep for surgeries” am…
The COVID-19 infection is no ordinary viral infection. Millions of people have succumbed to the virus globally and many have been hospitalized needing…